CareDx shows revenue growth of 19% but concerning margin expansion alongside deteriorating cash position and reduced receivables.
The company's gross profit substantially expanded relative to revenue growth, which could indicate improved operational efficiency or potentially unusual one-time benefits that warrant scrutiny. The 43% decline in cash position combined with increased debt levels suggests potential liquidity pressures or significant capital deployment that investors should monitor closely.
CareDx delivered solid revenue growth of 19% to $48.3M with operating cash flow modestly increasing to $42.0M, indicating healthy underlying business momentum. However, the balance sheet shows concerning trends with cash declining 43% to $65.4M, debt increasing 42% to $34.1M, and accounts receivable falling 34% to $42.6M, which collectively reduced total assets by 16% and stockholders' equity by 20%. The substantial gross profit expansion relative to revenue growth raises questions about sustainability and suggests investors should closely examine the components driving margin improvement.
Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.
Cash declined 43% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.
Debt increased 42.2% — substantial leverage increase; assess whether deployed for growth or covering losses.
Inventory surged 36.9% — growing faster than typical sales pace; potential demand softening or supply chain overcorrection.
Receivables declined — improved collection efficiency or conservative revenue recognition.
Current assets declined 26.9% — monitor working capital adequacy and short-term liquidity.
Equity decreased 19.9% — buybacks or losses reducing book value, monitor solvency ratios.
Revenue growing 18.9% — solid top-line momentum, watch margins for quality of growth.
Total assets contracted 15.8% — asset sales, write-downs, or balance sheet optimization underway.
Operating cash flow grew 10.5% — strong conversion of earnings to cash, healthy business fundamentals.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →